US Capitol Capsule: Liability unleashed? FDA generics proposal could mean lawsuits ahead
This article was originally published in Scrip
Executive Summary
A proposal by the FDA to allow generic drug makers to independently update their US product labeling with newly-acquired safety information before regulators review those changes could expose those manufacturers to liability when patients have adverse reactions – something those companies currently are protected against under two ruling by the US Supreme Court.